News
![heart-840x470](https://pharmaphorum.com/wp-content/uploads/2016/11/Heart-840x470.jpg)
BMS builds case for mavacamten label ahead of FDA decision
Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for th